Daniel Morgensztern, MD, on Perioperative Treatment of NSCLC: Findings From the KEYNOTE-671 Trial

Posted: Tuesday, March 5, 2024

Daniel Morgensztern, MD, of Washington University School of Medicine, discusses results from the KEYNOTE-671 trial, suggesting that among patients with resectable, early-stage NSCLC, neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab may improve outcomes vs neoadjuvant chemotherapy alone followed by surgery.